Patients with a diagnosis of EBV-associated HLH
Patient . | Age/sex . | NK LU . | % NK . | % perforin . | ||
---|---|---|---|---|---|---|
NK . | CD8 . | CD56 . | ||||
P8 | 1 y/M | 4.3 | <1↓ | 88 | 81↑ | 32 |
P5 | 2 y/M | NA | 1↓ | 96 | 26↑ | 24 |
P4 | 4 y/M | 0.02↓ | <1↓ | 82 | 9 | 28 |
P3 | 11 y/M | 0.00↓ | 3↓ | 85 | 66↑ | 76↑ |
Normal values | 1-15 y | >3.2 | 4-22 | 81-91 | 2-11 | 12-34 |
Patient . | Age/sex . | NK LU . | % NK . | % perforin . | ||
---|---|---|---|---|---|---|
NK . | CD8 . | CD56 . | ||||
P8 | 1 y/M | 4.3 | <1↓ | 88 | 81↑ | 32 |
P5 | 2 y/M | NA | 1↓ | 96 | 26↑ | 24 |
P4 | 4 y/M | 0.02↓ | <1↓ | 82 | 9 | 28 |
P3 | 11 y/M | 0.00↓ | 3↓ | 85 | 66↑ | 76↑ |
Normal values | 1-15 y | >3.2 | 4-22 | 81-91 | 2-11 | 12-34 |
Patients with EBV-associated HLH were generally older at diagnosis and were more likely to have very low numbers of NK cells and increased perforin-expressing CD8+ T cells. Perforin-expressing CD8+ T cells of patient P4 did not show an increased value, but the specimen of this patient was drawn a couple of weeks after initiation of therapy.
NA indicates not applicable.